GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Financial Strength

Anxo Pharmaceutical Co (ROCO:6677) Financial Strength : 3 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Financial Strength?

Anxo Pharmaceutical Co has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Anxo Pharmaceutical Co Ltd displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Anxo Pharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2023 was 2.16. Anxo Pharmaceutical Co's debt to revenue ratio for the quarter that ended in Jun. 2023 was 0.99. As of today, Anxo Pharmaceutical Co's Altman Z-Score is 1.93.


Competitive Comparison of Anxo Pharmaceutical Co's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Financial Strength falls into.



Anxo Pharmaceutical Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Anxo Pharmaceutical Co's Interest Expense for the months ended in Jun. 2023 was NT$-9.2 Mil. Its Operating Income for the months ended in Jun. 2023 was NT$19.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$528.1 Mil.

Anxo Pharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2023 is

Interest Coverage=-1*Operating Income (Q: Jun. 2023 )/Interest Expense (Q: Jun. 2023 )
=-1*19.791/-9.167
=2.16

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Anxo Pharmaceutical Co Ltd interest coverage is 3.83, which is low.

2. Debt to revenue ratio. The lower, the better.

Anxo Pharmaceutical Co's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(350.177 + 528.127) / 890.372
=0.99

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Anxo Pharmaceutical Co has a Z-score of 1.93, indicating it is in Grey Zones. This implies that Anxo Pharmaceutical Co is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 1.93 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anxo Pharmaceutical Co  (ROCO:6677) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Anxo Pharmaceutical Co has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Anxo Pharmaceutical Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Anxo Pharmaceutical Co (ROCO:6677) Business Description

Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines